Rebecca Abergel leads the BioActinide Chemistry Group at Berkeley Lab. Her research includes the study of heavy element coordination chemistry and biochemistry, and the design and development of advanced therapeutic and diagnostic agents for the mitigation of human contamination from radioactive heavy metals such as plutonium or uranium.
Recent research
- Berkeley Lab to Conduct R&D to Improve the Nation’s COVID-19 Testing Capabilities
- A Single Dose for Good Measure: How an Anti-Nuclear-Contamination Pill Could Also Help MRI Patients
- Separation Anxiety No More: A Faster Technique to Purify Elements
In the news
- VIDEO: #MyFaveElement: Plutonium
- Quoted in Chemical & Engineering News: Chemists explore the periodic table’s actinide frontier
- Quoted in California magazine: The Element Named After Berkeley
- MIT Technology Review’s Innovators Under 35 for A pill to decontaminate people after a radiation exposure
Keywords
COVID-19, radiation